Defective products allegedly cause blood clots in woman’s lung

There are now many forms of birth control for Florida residents to use in order to prevent pregnancy. Some of them can affect the body and cause side effects. One woman got more than she bargained for when she developed a pulmonary embolism from using the NuvaRing.

The Pennsylvania woman started using the device in March 2012. The following month, she noticed a shortness of breath and chest pain. She saw a cardiologist, who recommended a CT scan. A scan of her right lung showed emboli. This resulted in a hospital stay so that the woman could begin anticoagulation therapy.

The woman, age 41 at the time of the incident, has filed a lawsuit, which makes several complaints. The package insert allegedly focuses on minor side effects and lists safety information not associated with NuvaRing studies. The manufacturers made no mention of embolisms, deep vein thrombosis or even death. The lawsuit also alleges that the manufacturers did not fully test the product and regulate its release of estrogen before putting it on the market.

The woman claims that all her injuries were caused by the NuvaRing and would not have used it had she known about the risks. She is suing Merck & Co. Inc., Merck Sharp & Dohme, Organon, Schering Corp and Organon USA Inc., N.V. for selling defective products. She is claiming negligence, breach of warranty, misrepresentation and lack of consumer protection, and she is seeking more than $75,000 in damages.

The woman continues to seek medical treatment for the medical issues caused by the NuvaRing. She also must continue to take medication. Because of this, she is within her legal rights to sue the manufacturer, especially if she was not warned about the risks beforehand. Medications such as birth control are not risk-free products and should not be marketed as such. Although women are always looking for new ways to delay childbirth, they want safe options.

The Pennsylania Record, “York Co. woman files NuvaRing products liability complaint” Jon Campisi, Nov. 18, 2013